Quarry LP’s Viridian Therapeutics VRDN Stock Holding History

Quarry LP’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-801	Closed	-$17.3K	–	2660
2025 Q3	$17.3K	Buy	+801	New	+$14.4K	﹤0.01%	1480

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Quarry LP's VRDN Position: Q4 2025 in Review

Quarry LP sold out of Viridian Therapeutics (VRDN) in Q4 2025, closing a stake of 801 shares — an estimated $17.3K sold.

Quarry LP first reported a position in VRDN in Q3 2025 and held it in 1 quarter. The position peaked at $17.3K in Q3 2025. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

Quarry LP reported no remaining Viridian Therapeutics position as of Q4 2025 after selling out during the quarter.
Quarry LP sold 801 Viridian Therapeutics shares in Q4 2025, an estimated $17.3K.
Quarry LP first reported a position in Viridian Therapeutics in Q3 2025 and held it in 1 quarter.
Quarry LP's Viridian Therapeutics position peaked at $17.3K in Q3 2025.
229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on Quarry LP's 13F filing for Q4 2025, filed 13 Feb 2026.